Literature DB >> 10022415

Acute and short-term effects of growth hormone on insulin-like growth factors and their binding proteins: serum levels and hepatic messenger ribonucleic acid responses in humans.

H Olivecrona1, A Hilding, C Ekström, H Barle, B Nyberg, C Möller, P J Delhanty, R C Baxter, B Angelin, T J Ekström, M Tally.   

Abstract

We investigated the acute (4-5 h) and short-term (5 days) effects of GH treatment on hepatic messenger RNA (mRNA) levels of the genes for the insulin-like growth factors (IGFs), insulin-like growth factor binding protein-1, -2, and -3 (IGFBPs), and the acid labile subunit (ALS), as well as serum levels of these proteins in humans. At the mRNA level, we observed an increase in IGF-1 transcription (+173%) following GH treatment in the acute group, which remained elevated in the short-term treatment group. IGFBP-2 mRNA decreased after short-term GH treatment, without changes in IGFBP-1 or -3 expression. The ALS transcript level increased after 5 days. In serum, we found increased levels of IGF-I and insulin, and decreased levels of IGF-II, in the short-term treatment group. IGFBP-1 decreased in both treatment groups, whereas IGFBP-2 was reduced after 5 days treatment. ALS increased in the short-term group. We observed increased IGFBP-3 serum levels after 5 days of GH treatment, likely due to increased formation of the ternary complex. Our results show that the metabolic effects by GH on the IGF axis are complex. In addition to a direct stimulation of IGF-I and ALS expression, GH inhibits IGFBP-1 serum levels and IGFBP-2 expression in an indirect manner, possibly facilitating enhanced IGF bioavailability to target tissues.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10022415     DOI: 10.1210/jcem.84.2.5466

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results.

Authors:  Francesco Saccà; Mario Quarantelli; Carlo Rinaldi; Tecla Tucci; Raffaele Piro; Gaetano Perrotta; Barbara Carotenuto; Angela Marsili; Vincenzo Palma; Giuseppe De Michele; Arturo Brunetti; Vincenzo Brescia Morra; Alessandro Filla; Marco Salvatore
Journal:  J Neurol       Date:  2011-06-25       Impact factor: 4.849

Review 2.  Implications of the PAPP-A-IGFBP-IGF-1 pathway in the pathogenesis and treatment of polycystic kidney disease.

Authors:  Sonu Kashyap; Julianna D Zeidler; Claudia C S Chini; Eduardo Nunes Chini
Journal:  Cell Signal       Date:  2020-06-20       Impact factor: 4.315

Review 3.  Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis.

Authors:  A Grimberg; P Cohen
Journal:  J Cell Physiol       Date:  2000-04       Impact factor: 6.384

Review 4.  Targeting insulin-like growth factor-I and insulin-like growth factor-binding protein-3 signaling pathways. A novel therapeutic approach for asthma.

Authors:  Hyun Lee; So Ri Kim; Youngman Oh; Seong Ho Cho; Robert P Schleimer; Yong Chul Lee
Journal:  Am J Respir Cell Mol Biol       Date:  2014-04       Impact factor: 6.914

5.  IGF-I and IGFBP-3 and the risk of lung cancer: a meta-analysis based on nested case-control studies.

Authors:  Bo Chen; Shan Liu; Wei Xu; Xueli Wang; Weihong Zhao; Jianqing Wu
Journal:  J Exp Clin Cancer Res       Date:  2009-06-24

Review 6.  IGF binding proteins in cancer: mechanistic and clinical insights.

Authors:  Robert C Baxter
Journal:  Nat Rev Cancer       Date:  2014-04-10       Impact factor: 60.716

Review 7.  Unraveling insulin-like growth factor binding protein-3 actions in human disease.

Authors:  Sherryline Jogie-Brahim; David Feldman; Youngman Oh
Journal:  Endocr Rev       Date:  2009-05-28       Impact factor: 19.871

8.  Altered expression of members of the IGF-axis in hepatoblastomas.

Authors:  S G Gray; T Eriksson; C Ekström; S Holm; D von Schweinitz; P Kogner; B Sandstedt; T Pietsch; T J Ekström
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

9.  Combined sprint and resistance training abrogates age differences in somatotropic hormones.

Authors:  Maha Sellami; Wissem Dhahbi; Lawrence D Hayes; Johnny Padulo; Fatma Rhibi; Hanen Djemail; Anis Chaouachi
Journal:  PLoS One       Date:  2017-08-11       Impact factor: 3.240

10.  Circulating Insulin-Like Growth Factor-1 and Risk of Total and 19 Site-Specific Cancers: Cohort Study Analyses from the UK Biobank.

Authors:  Frank Qian; Dezheng Huo
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-08-20       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.